CHICAGO, June 23, 2011 /PRNewswire-FirstCall/ — Mr.
Ronald L. Chez, a private investor, filed an amended 13D for
RepliGen Corporation (Nasdaq:
RGEN) with the SEC.
RepliGen Corporation is a biopharmaceutical
company focused on building an integrated company by developing and
marketing innovative drugs that deliver the benefits of protein
therapies in the fields of neurology and gastroenterology.
RepliGen has a core competency in the development and manufacturing
of biologics products, which serve as the basis for the
bioprocessing business. RepliGen has out-licensed certain biologics
intellectual property, which provide an ongoing source of revenue.
RepliGen’s corporate headquarters are located in Waltham,
Mr. Ronald L. Chez is the President of Ronald L. Chez, Inc., and
a private investor.